Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial

IMPORTANCE: Bayesian clinical trial designs are increasingly common; given their promotion by the US Food and Drug Administration, the future use of the bayesian approach will only continue to increase. Innovations possible when using the bayesian approach improve the efficiency of drug development...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, Donald A., Dhadda, Shobha, Kanekiyo, Michio, Li, David, Swanson, Chad J., Irizarry, Michael, Kramer, Lynn D., Berry, Scott M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091161/
https://www.ncbi.nlm.nih.gov/pubmed/37040116
http://dx.doi.org/10.1001/jamanetworkopen.2023.7230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091161/
https://www.ncbi.nlm.nih.gov/pubmed/37040116
http://dx.doi.org/10.1001/jamanetworkopen.2023.7230

Ejemplares similares